tbResList Print — ATO Arsenic trioxide

Description: <b>Arsenic</b> has been known for centuries for its toxic and medicinal properties. Although once infamously used as a poison, ongoing research has repurposed arsenic derivatives for medicinal use.</br>

<p><b>Arsenic trioxide</b> — Arsenic trioxide (As₂O₃) is an intravenously administered inorganic small-molecule antileukemic agent best known for targeting acute promyelocytic leukemia (APL) biology, where it promotes degradation of the PML–RARα oncoprotein and restores differentiation programs while also engaging oxidative/mitochondrial stress pathways. It is a regulated prescription drug (injectable solution; oncology use). Standard abbreviation(s): ATO. Clinically, it is established therapy for APL (including in combination with all-trans retinoic acid, ATRA/tretinoin) and requires strict cardiac/electrolyte and toxicity monitoring due to potentially fatal QT prolongation/arrhythmia and other boxed-warning risks.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>PML–RARα oncoprotein damage/degradation with downstream re-formation of PML nuclear bodies, differentiation reprogramming, and loss of leukemia-initiating capacity (APL-centric)</li>
<li>Pro-apoptotic stress signaling (mitochondrial dysfunction, DNA fragmentation phenotype in APL models)</li>
<li>Oxidative stress and redox remodeling with downstream stress-response signaling (context-dependent; contributes to cytotoxicity and/or sensitization)</li>
<li>Metabolic suppression in some solid-tumor models (e.g., glycolysis/LDHA axis inhibition reported in specific contexts; not a primary, label-defined mechanism)</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> Delivered IV (standard clinical product). In solution it forms arsenious acid (AsIII), the pharmacologically active species; major circulating metabolites include MMAV and DMAV with longer half-lives and greater accumulation vs AsIII. AsIII shows wide tissue distribution (large Vss). Exposure is regimen-driven (oncology dosing) rather than “nutraceutical-like” oral titration; oral ATO exists in research/region-specific formulations but is not the default reference for labeled TRISENOX use.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Many mechanistic findings outside APL (ROS/metabolic axes) are concentration- and model-dependent; do not assume that solid-tumor in-vitro concentrations map cleanly onto clinically tolerated systemic exposure given dose-limiting cardiac and systemic toxicities.</p>

<p><b>Clinical evidence status:</b> Established, guideline-level therapy in APL with randomized phase 3 evidence supporting ATRA+ATO regimens in low/intermediate-risk APL; also indicated for relapsed/refractory APL. Broader “anti-glycolysis/anti-migration” positioning is preclinical/adjunct-hypothesis level outside APL.</p>



<h3>Arsenic trioxide — cancer-relevant mechanistic axes (ranked)</h3>
<table>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>

<tr>
<td>1</td>
<td>PML–RARα proteostasis and differentiation program</td>
<td>↓ PML–RARα (APL); ↑ differentiation; ↓ self-renewal capacity</td>
<td>Not target-defining in most normal tissues</td>
<td>G</td>
<td>Oncoprotein elimination and differentiation-based disease control</td>
<td>Core, clinically validated axis in APL; most “ATO = drug” value is anchored here.</td>
</tr>

<tr>
<td>2</td>
<td>Cardiac electrophysiology constraint</td>
<td>—</td>
<td>↑ QTc risk; ↑ torsade risk (with electrolyte/QT-prolonging co-meds)</td>
<td>P/R</td>
<td>Dose-limiting safety axis</td>
<td>Boxed warning includes QT prolongation/ventricular arrhythmias; mandates ECG + K/Mg management.</td>
</tr>

<tr>
<td>3</td>
<td>Apoptosis and DNA fragmentation phenotype</td>
<td>↑ apoptosis (APL models); ↑ DNA fragmentation phenotype</td>
<td>Context-dependent toxicity</td>
<td>R</td>
<td>Cytotoxic stress response</td>
<td>Mechanism is “not completely understood” on label; apoptosis phenotype is consistently described for APL cell models.</td>
</tr>

<tr>
<td>4</td>
<td>Mitochondria and bioenergetics</td>
<td>↓ ATP (model-dependent)</td>
<td>Context-dependent mitochondrial toxicity</td>
<td>R</td>
<td>Bioenergetic stress</td>
<td>Nestronics indexing flags ATP↓ in cancer/diseased cells; often mechanistically tied to ROS/apoptosis networks rather than a single ETC target.</td>
</tr>

<tr>
<td>5</td>
<td>ROS and redox stress (secondary)</td>
<td>↑ ROS (context-dependent); redox-driven signaling shifts</td>
<td>↑ oxidative stress risk (context-dependent)</td>
<td>P/R</td>
<td>Stress amplification and sensitization potential</td>
<td>Frequently invoked in preclinical literature; translation constrained by systemic toxicity and disease context.</td>
</tr>

<tr>
<td>6</td>
<td>Core metabolism / glycolysis axis</td>
<td>↓ glycolysis (model-dependent); ↓ lactate production; ↓ LDHA/PGK1/PGM1 (reported in specific models)</td>
<td>↔ / context-dependent</td>
<td>G</td>
<td>Metabolic suppression in select tumor models</td>
<td>Nestronics pathways emphasize glycolysis-related downshifts (solid-tumor paper indexing). Outside APL, treat as hypothesis-level and model-specific.</td>
</tr>

<tr>
<td>7</td>
<td>Migration / invasion phenotype</td>
<td>↓ migration/invasion phenotypes (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Anti-motility signaling (context-dependent)</td>
<td>Nestronics flags reduced tumor cell invasion/migration/proliferation phenotypes; not a label-defined therapeutic claim.</td>
</tr>

<tr>
<td>8</td>
<td>Drug resistance and efflux</td>
<td>↑ efflux signatures (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Adaptive resistance pressure</td>
<td>Nestronics flags efflux ↑ as a resistance axis; clinically, regimen design and monitoring dominate over “efflux targeting.”</td>
</tr>

<tr>
<td>9</td>
<td>Clinical Translation Constraint</td>
<td>APL benefit is high; broad solid-tumor translation limited</td>
<td>Systemic toxicity limits exposure</td>
<td>—</td>
<td>Therapeutic window and monitoring burden</td>
<td>Key constraints: QTc prolongation/arrhythmia risk, differentiation syndrome risk, encephalopathy/Wernicke’s risk, hepatic/renal impairment considerations; IV delivery standard for TRISENOX.</td>
</tr>
</table>
<p><b>TSF legend:</b> P: 0–30 min &nbsp; R: 30 min–3 hr &nbsp; G: &gt;3 hr</p>